THE TRIALNET NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 TrialNet联盟的主要目的是在有患T1D风险的个人或新诊断的T1D患者身上开发保护胰腺细胞功能的治疗方法的临床试验。这些试验的最佳设计和完成取决于对T1D自然病史的了解和招募受试者的有效策略。1型糖尿病发展的TrialNet自然病史研究的目标是获得有关T1D的自然病史和发病机制的信息，并促进招募和评估可能有资格参加T1D预防试验的个人。 T1D发展的TrialNet自然历史研究分为三个阶段：第一阶段筛选、第二阶段基线风险评估和第三阶段后续风险评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of the TrialNet consortium is to develop clinical trials of treatments that protect pancreatic ¿-cell function, in individuals who are at risk for developing T1D or who have newly diagnosed T1D. Optimal design and completion of these trials depends upon knowledge of the natural history of T1D and effective strategies to recruit subjects. The goals of the TrialNet Natural History Study of the Development of Type 1 Diabetes are to gain information about the natural history and pathogenesis of T1D and to facilitate the recruitment and assessment of individuals who might qualify for T1D prevention trials. The TrialNet Natural History Study of the Development of T1D is divided into three phases: Phase 1 Screening, Phase 2 Baseline Risk Assessment, and Phase 3 Follow-Up Risk Assessment.